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ABSTRACT
Until last year, terrorism, economic instability, poverty and natural disasters were considered the major 
threats to humans globally. Infectious diseases were seen as a minor problem. This, however, changed 
in 2020 when the global COVID-19 pandemic broke out and a new danger emerged. The latest events 
generated a lot of discussion on health hazards associated with international tourism and uncontrolled 
spread of pathogens across the borders. The major health problems of travelers to developing countries 
with harsh environmental conditions and endemic infectious diseases include gastrointestinal disorders, 
dermatoses, respiratory infections and fevers of unknown origin. A medical interview by an experienced 
physician is the foundation of the post-travel screening process both in symptomatic and asymptomatic 
travelers; the interview should focus on identifying exposure to risk factors (endemic infectious diseases, 
failure to adopt disease prevention measures, consumption of food or water from unsafe sources, insect 
bites, animal bites, travelling in large groups, unsafe sex with casual partners). While physical examination 
(identification of abnormalities) and diagnostic tests (identification of pathogens) can be useful for detec-
ting illnesses and asymptomatic infections as well as assessing the general health condition of a patient, 
including his immune system. The aim of the article is to provide information on the post-travel screening 
process in symptomatic and asymptomatic travelers who have returned from areas with harsh climate 
conditions and low sanitation standards.
(Int Marit Health 2020; 71, 2: 129–139)
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INTRODUCTION
According to the World Tourism Organization (UNWTO), 
there were 1.5 billion international tourist arrivals world-
wide in 2019. The gradually increasing number of interna-
tional tourist arrivals seen in recent years (+6% in 2017, 
+6% in 2018, +4% in 2019) was predicted to reach a spec-
tacular level of 1.8 billion in 2030. All regions saw a rise in 
tourism in 2019 compared to the previous year (Asia and 
the Pacific +5%, Europe and Africa both +4%, the Americas 
+2%). According to the estimates, a growth of 3–4% was 
predicted for 2020 [1]. However, the COVID-19 pandemic 
has brought the tourist industry to a halt, and the earlier 
forecasts had to be revised. Most experts believe that 
the domestic demand for travelling and travel services is 
likely to rise faster than international tourism; whereas 
the international demand is predicted to grow faster in 
Africa and the Middle East, where the number of active 
SARS-CoV-2 cases and COVID-19 deaths is much smaller 
compared to the European countries or North America [1]. 
The restrictions imposed on international air transport, 
travel agencies, hotels and restaurants will certainly have 
a significant impact on the economies of many countries, 
especially those in which tourism accounts for a significant 
proportion of Gross Domestic Product. According to the 
UNWTO estimates, the number of international tourist 
arrivals may drop by 60–80% in 2020 (compared to 2019; 
a loss of 850 million to 1.1 billion) [2]. The most visited 
countries by tourists in the world have reported both a very 
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Table 1. The most visited countries by tourists versus number of detected SARS-CoV-2 infections and COVID-19 deaths, 29 May 2020
Country Tourist arrivals in millions  
in 2018 [3]
SARS-CoV-2 infections [4] COVID-19 deaths [4]
France 89 186,835 28,714
Spain 83 285,644 27,121
USA 80 1,793,530 104,542
China 63 82,995* 4,634*
Italy 62 232,248 33,229
*According to Chinese sources; USA — United States of America
large number of SARS-CoV-2 cases and COVID-19 deaths 
(Table 1) [3, 4].
The countries whose economies almost entirely rely on 
tourism, e.g. the Caribbean or the Pacific Islands, are likely 
to be affected by a serious economic crisis. But the global 
downturn may also affect the European Union countries, 
where the tourism industry offers employment to 12% of 
the economically active people and generates an income 
of 400 billion euro per year. Some countries, e.g. Greece 
or Croatia have been considering the introduction of the 
so-called ‘tourist corridors’ linking the popular resorts with 
countries least affected by the pandemic or those where 
the SARS-CoV-2 epidemic has been successfully contained, 
without a mandatory 14-day quarantine upon arrival. It is 
also planned to introduce COVID safety certificates for the 
re-opening hotels, restaurants and other tourist facilities to 
ensure that re-opening those businesses will not increase 
the risk of spreading COVID-19. Some countries are also dis-
cussing the introduction of ‘immunity passports’, a digital or 
paper document that will certify that an individual has been 
infected with SARS-CoV-2 and is immune to COVID-19 [5]. 
Turkey is planning to re-open its borders only for foreign tour-
ists with a negative SARS-CoV-2 test result; visitors will be 
required to present the test result upon arrival. The Canary 
Islands in collaboration with the Department of Innovation 
and Digital Transformation (UNWTO) are working on a new 
project aimed at the introduction of digital health passports 
(a mobile phone application developed by Hi+ Card) for all 
tourists visiting the islands this summer. The application will 
contain the visitors’ medical data certifying they are free of 
COVID-19 and will allow the authorities real-time tracking of 
travelers (for which the travelers grant their consent when 
installing the application). All these measures are meant to 
rebuild the tourism industry, which is a major branch of the 
global economy, as fast as possible.  
Until 2019, it seemed that the major travel-associated 
threats to humans were terrorism (the Middle East, North 
Africa), socio-economic instability (Venezuela) and natural 
disasters (earthquakes and floods). Infectious diseases 
were further down the list, next to petty crimes or traffic 
accidents. In 2018, the World Health Organization (WHO) 
published a list of priority diseases which are a top threat to 
public health globally because of their pandemic potential, 
the first on the list were viral hemorrhagic fevers (Ebola, Mar-
burg, Lassa, Crimean-Congo), coronavirus infections (MERS, 
SARS) and Disease X (a placeholder name for currently 
unknown disease, possibly a viral zoonosis) [6]. In January 
2020, Disease X turned out to be COVID-19, an infection 
which originated in the Chinese province of Hubei and its 
capital, Wuhan and caused a global pandemic. Two years 
ago, the WHO stressed how important it is to improve the 
quality of healthcare systems around the world to be able to 
control the possible future outbreak and prevent the spread 
of diseases. Will the ongoing COVID-19 pandemic raise 
public awareness of the importance of post-travel health 
assessment, especially in those travelers who are returning 
from countries where infectious diseases are endemic? 
Now seems to be the right time to initiate discussion on 
travel-related health risk factors and uncontrolled spread 
of pathogens across the borders. The aim of the article is 
to provide information on the post-travel screening process 
in symptomatic and asymptomatic travelers returned from 
areas with harsh climate conditions and low sanitation 
standards. 
INFECTIOUS DISEASES IMPORTED  
BY POLISH TRAVELERS 
The Polish National Institute of Public Health – National 
Institute of Hygiene, the Department of Epidemiology and 
Surveillance of Infectious Diseases publishes a report on 
cases of infectious diseases and poisonings in Poland every 
2 weeks. The report includes both domestic and import-
ed cases. Influenza and influenza-like illness are at the 
top of the list: a total of 4,789,827 cases were reported 
in 2019 (5,239,293 in 2018) [7]. Unfortunately, most of 
these diagnoses are not confirmed by a laboratory test 
and therefore a large proportion of illnesses manifesting 
with similar clinical signs (fever, osteoarticular and muscle 
pain, general weakness) may be mistakenly reported as 
influenza or parainfluenza. These may include imported 
tropical diseases such as malaria or arboviral infections 
(dengue, chikungunya, zika). According to the reports, there 
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were 25 confirmed cases of imported malaria, 55 cases of 
dengue, 2 cases of chikungunya and zero cases of zika in 
2019 (in 2018, the number of confirmed cases was report-
ed to be 28,30,0,1 infections, respectively) [7]. The actual 
number of other tropical infections (e.g. schistosomiasis, 
filariases, leishmaniases) or cosmopolitan diseases which 
are endemic in developing countries (ascariasis, trichuriasis, 
hookworm) in returned travelers is not known. There are two 
major reasons for this — the first is the lack of testing, and 
the second the lack of obligation to report the diseases to 
competent authorities. As was mentioned before, Polish 
patients are rarely screened for tropical diseases (even if 
a patient who has returned from a tropical country reports 
fever of unknown origin, post-travel screening is hardly ever 
recommended since Polish laboratories do not offer test 
panels for the detection of tropical diseases). Therefore, 
it is likely that some imported tropical infections may be 
misdiagnosed as cosmopolitan diseases. In such cases 
patients will only receive symptomatic treatment, and the 
real etiological factor will never be discovered. Asymptom-
atic carriers are especially problematic from a public health 
perspective because they can transmit the infection to other 
people without knowing it. Previous studies by the author, 
which involved groups of Polish soldiers deployed on military 
missions to Central Asia and the Middle East, demonstrated 
significant numbers of asymptomatic infections caused by 
intestinal parasites [8] and hepatitis E virus (HEV) [9].
COMMON HEALTH PROBLEMS  
OF INTERNATIONAL TRAVELERS
It has been estimated that as many as 43–79% of trav-
elers from European or North American countries are likely 
to experience a travel-related health problem during or after 
travel to a developing country [10]. Most of these travelers 
will have mild symptoms, while 1–5% will seek medical 
care from a health care provider. A majority of travel-related 
conditions have a short incubation time with symptoms 
manifesting during or shortly after travel; there are some 
diseases, however, which have much longer incubation pe-
riods and whose symptoms tend to manifest weeks or even 
months after returning home. Travelers who have recently 
returned from a country where infectious diseases are en-
demic should inform their health care provider of this fact. 
A post-travel medical interview should primarily focus on 
the following questions: vaccinations received before trav-
el; compliance with antimalarial chemoprophylaxis before, 
during and after travel; the use of insect repellents during 
travel; disease symptoms which occurred during travel and 
medications taken to treat the symptoms; countries visited, 
the length of stay, the type of accommodation; travel to large 
population centers; consumption of the local food; insect 
bites (mosquitoes, sand flies, ticks); animal bites; unsafe 
sex with casual partners (local people or other travelers); 
surgical procedures, blood transfusions, injections, tattooing 
[11–14]. The most common health conditions in travel-
ers to destinations with harsh environmental conditions 
and endemic infectious diseases include gastrointestinal 
disorders, dermatoses, respiratory illnesses and fevers of 
unknown origin [15].   
GASTROINTESTINAL DISORDERS
The most common gastrointestinal conditions in trav-
elers include acute diarrheas (defined as a minimum of 
three loose stools within 24 h or an increase in stool weight 
> 200 g/day associated with increased stool liquidity, lasting 
for no longer than 14 days; mainly of bacterial [Escherichia 
coli, Salmonella, Shigella, Campylobacter] or less often 
of viral etiology [Norwalk, adenoviruses and rotaviruses]). 
These are commonly referred to as travelers’ diarrhea (symp-
toms usually resolve spontaneously after a few days). Some 
returned travelers, however, may experience persistent 
diarrheas (lasting longer than 14 days), which are usually 
of parasitic etiology (Giardia intestinalis, Cryptosporidium 
parvum, Entamoeba histolytica). The diagnosis of suspected 
bacterial diarrheas is based on conventional microbiological 
methods (stool culture). The test is recommended if blood 
or pus is present in the stool, also in febrile or immunode-
ficient patients and patients with chronic conditions. The 
diagnosis of viral diarrheas relies on molecular methods 
(polymerase chain reaction [PCR]), while the gold standard 
for the diagnosis of parasitic diarrhea is the multiple fecal 
tests, i.e. examining of stool (at least three samples) by 
light microscopy, preferably using concentration techniques 
(sedimentation for the detection of protozoa and flotation 
for the detection of helminths). Persistent diarrheas should 
be differentiated from non-infectious or post-infectious con-
ditions, such as the malabsorption syndrome or the irritable 
bowel syndrome. The malabsorption syndrome caused by 
impaired absorption of food nutrients in the gastrointestinal 
tract is often associated with celiac disease (gluten-sensi-
tive enteropathy), cystic fibrosis, chronic pancreatitis or 
pancreatic cancer, status post gastrectomy, enzymatic de-
ficiencies (lactase deficiency causing lactose intolerance, 
sucrase-isomaltase deficiency — sucrose intolerance aldo-
lase deficiency — fructose intolerance). Irritable bowel syn-
drome, on the other hand, is an idiopathic gastrointestinal 
disorder of unknown etiology characterized by abdominal 
pain, flatulence and defecation disorders (diarrhea or con-
stipation) [11, 14, 16].
DERMATOSES
The most common skin problems found in returned 
travelers include allergic reactions to insect bites (scratching 
the lesions may cause a secondary pyoderma, erosions or 
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ulcerative lesions), allergic rash, superficial skin lesions 
(epidermal abrasion, animal bites or scratches, sunburns, 
exposure to marine animals, e.g. jellyfish stings), pyodermas 
(folliculitis, furuncles, abscess), fungal infections. Tropical 
dermatoses, such as an arboviral infection presenting with 
a skin rash (dengue, chikungunya, zika), cutaneous larva 
migrans or myiasis are rarely seen in travelers. The diagno-
sis of skin lesions is based on identifying the type of lesion 
(maculopapular or papular rash, nodules, vesicular/bullous 
rash, pustules, erosions/ulcers), its location (hairless or 
hairy skin, armpits, groins, joints), etiological factor (insect 
bites, exposure to sun, exposure to pathogens — viruses, 
bacteria, parasites, fungi) and associated symptoms (pru-
ritus, pain, burning sensation, fever) [17].  
RESPIRATORY INFECTIONS
The most common respiratory illnesses diagnosed in 
returned travelers include upper respiratory tract infections 
(a cold, pharyngitis, tonsillitis, sinusitis). Lower respiratory 
tract infections (e.g. pneumonia) are less common but pres-
ent with more pronounced signs and symptoms (fever, chest 
pain, cough, dyspnea) and therefore may require in-hospital 
treatment. Respiratory illnesses are most often caused 
by viruses (influenza viruses, adenoviruses, rhinoviruses, 
coronaviruses) and bacteria (Streptococcus pneumoniae, 
Mycoplasma pneumoniae, Haemophilus influenzae, Chlam-
ydophila pneumoniae, Legionella pneumophila). Tropical 
pathogens are rarely responsible for respiratory infections in 
travelers. Mass infections may occur during organized tours, 
in hotels, on cruise ships or passenger aircrafts (droplet or 
airborne transmission). The diagnosis of a respiratory illness 
is based on the identification of the etiological factor either 
by molecular methods (viruses) or standard microbiological 
techniques, e.g. culture (bacteria). The biological material 
used for testing is usually a sputum or nasopharyngeal 
swab sample, a bronchoscopy sample or tracheal aspirate 
samples; the standard imaging method for the diagnosis of 
respiratory illnesses include a sinus or a chest X-ray [18].
FEVERS OF UNKNOWN ORIGIN
Malaria is a common cause of fever in travelers return-
ing from tropical or subtropical destinations (infection with 
Plasmodium parasite through a bite of an infected mosqui-
to). Other common travel-related febrile illnesses include 
dengue, chikungunya, zika (arboviral infections transmitted 
by mosquitoes), viral hepatitis A, typhoid fever (transmitted 
through the fecal-oral route) and rickettsioses (transmit-
ted by lice, fleas, ticks, mites). Febrile illnesses may be of 
non-tropical origin as well and be a sign of a respiratory or 
a urinary tract infection; fever may also be an accompanying 
symptom of many dermatoses, e.g. burns. A febrile patient 
is likely to have other symptoms as well (headache, general 
weakness, muscle and joint pain, gastrointestinal disorders, 
shin rash, conjunctivitis) which may be important for the 
differential diagnosis; most febrile illnesses have a short 
incubation period and tend to manifest within 4 weeks after 
traveler’s return. Some conditions, however, have longer in-
cubation periods and can manifest themselves many weeks 
after return; these include Plasmodium vivax malaria, tuber-
culosis or viral hepatitis. The onset of fever may be gradual 
and eventually reach a very high level and be associated 
with bradycardia (as in typhoid), or abrupt as in dengue. 
Malaria is typically characterized by a sudden onset of fever 
which is then recurring in cycles. In Plasmodium vivax and 
P. ovale infections, fever paroxysms occur periodically every 
48 hours, in P. malariae infection — every 72 hours. Fever 
paroxysms in P. falciparum malaria are irregular and ele-
vated body temperature of varying degree can persist all 
throughout the duration of the symptomatic disease. When 
diagnosing a febrile patient who has returned from a tropical 
destination, malaria should be ruled out first (the thick and 
thin blood smears) before proceeding with further tests. It 
is then recommended to perform serological tests to rule 
out arboviral infections (dengue, chikungunya, zika), tests 
to detect infections which are endemic in the visited part 
of the world (HAV, HEV), blood count with differential, liver 
enzymes levels, urinalysis, C-reactive protein (CRP), a chest 
X-ray, stool microscopy (detection of parasites) and, in justi-
fied cases, blood, urine and stool culture [19]. 
Most travel-related illnesses tend to manifest within 
a few weeks after traveler’s return (Tables 2, 3). Some 
conditions, however, have longer incubation periods and 
their symptoms may manifest 6 or more weeks after coming 
back home. For this reason a medical interview forms the 
basis of post-travel assessment. A febrile illness occurring 
more than 3 weeks after return almost certainly rule out 
dengue or rickettsioses. A late onset of symptoms may 
be suggestive of visceral, cutaneous or mucocutaneous 
leishmaniasis, chronic Chagas disease, chronic brucello-
sis, malaria or schistosomiasis. The accuracy of a clinical 
diagnosis and the effectiveness of treatment will much de-
pend on a patient himself. In order to establish an accurate 
diagnosis, a physician needs to know of all the risk factors 
a patient might have been exposed to during travel (Table 4). 
If patients conceal or omit any significant information from 
their health care provider, it will be more difficult for a physi-
cian to make an accurate diagnosis and implement effective 
treatment [11, 20, 21].
TYPES OF EXAMINED TRAVELERS
Post-travel assessment is primarily recommended to:
 — symptomatic travelers who experience symptoms of an 
infection on their return or within three months after 
return, especially if they experience fever, persistent 
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Table 2. Incubation period and disease symptoms [20]
Incubation  
period
Symptoms Disease
< 2 weeks Fever + non-specific symptoms Malaria, dengue, chikungunya, zika, campylobacteriosis, salmonellosis, shigellosis, 
African trypanosomiasis, leptospirosis, typhoid fever
< 2 weeks Fever + coagulation disorders Invasive meningococcal disease, leptospirosis, malaria, viral hemorrhagic fevers
< 2 weeks Fever + neurological symptoms Malaria, typhoid fever, rickettsioses, invasive meningococcal disease, rabies,  
African trypanosomiasis, poliomyelitis, encephalitis and/or meningitis
< 2 weeks Fever + respiratory symptoms Influenza, COVID-19, common cold, streptococcal pharyngitis/pneumonia,  
legionellosis, Q fever
< 2 weeks Fever + skin lesions Rubella, varicella, measles, herpes simplex, dengue, chikungunya, zika, rickettsioses, 
typhoid fever, HIV infection
2–6 weeks A variety of symptoms: fever 
+ neurological or respiratory 
symptoms or skin lesions
Malaria, tuberculosis, hepatitis A, hepatitis B, acute hepatitis C, hepatitis E, 
leishmaniasis, acute schistosomiasis (Katayama syndrome), amebic liver abscess, 
leptospirosis, African trypanosomiasis, Chagas disease, viral hemorrhagic fevers,  
Q fever, measles, typhoid fever
> 6 weeks A variety of symptoms: fever 
+ neurological or respiratory 
symptoms or skin lesions
Malaria, tuberculosis, hepatitis B, acute hepatitis C, hepatitis E, leishmaniasis, 
wuchereriasis, onchocerciasis, schistosomiasis, amebic liver abscess, African 
trypanosomiasis
Table 3. Incubation period and geographic regions [12, 21]
Incubation period Geographic regions Disease
6–30 days (98% onset within  
3 months of travel)
Especially in Sub-Saharan Africa (> 90%), also in Central and South 
America, India and South-East Asia
Malaria, Plasmodium 
falciparum
8 days to 12 months (50% have 
onset > 30 days after completion 
of travel) 
Especially in Central and South America, India and South-East Asia, 
also in Sub-Saharan Africa
Malaria, Plasmodium vivax
4–8 days (range 3–14 days) South-East Asia, Central and South America, Africa, Pacific islands Dengue
2–4 days (range 1–14 days) South-East Asia, Central and South America, Africa Chikungunya
3–14 days South-East Asia, Central and South America, Africa, Pacific islands Zika
< 21 days Democratic Republic of the Congo (Ebola), Nigeria (Lassa); the 
Middle East, the Balkans, Central Asia, Africa (Crimean-Congo)
Viral hemorrhagic fevers
2–14 days Arabian Peninsula MERS-CoV
2–14 days Cosmopolitan COVID-19
1–3 days Cosmopolitan Influenza
5–6 days (range 2–10 days) Cosmopolitan Legionellosis
3–8 days Sub-Saharan Africa, South America Yellow fever
3–6 days (range 1–20 days) Africa, Asia, Europe West Nile fever
3–14 days (range 1–20 days) South and South-East Asia (from India to Japan) Japanese encephalitis
28–30 days (range 15–50 days) Cosmopolitan Hepatitis A
26–42 days (range 2–9 weeks) Cosmopolitan Hepatitis E
6–30 days (range 3–60 days) Cosmopolitan (especially in Indian subcontinent) Typhoid fever
7–14 days Cosmopolitan, epidemics Epidemic typhus
7–12 days (range 2–26 days) Cosmopolitan (especially in Asia) Leptospirosis
4–8 weeks Sub-Saharan Africa, South-East Asia, South America Acute schistosomiasis 
(Katayama syndrome)
2–6 months (range 10 days to 
years)
Mediterranean, Africa, Asia, Central and South America Leishmaniasis (cutaneous, 
visceral, mucocutaneous) 
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Table 4. Risk factors (exposures and activities) [21]
Risk factors Disease
Contact with fresh water Schistosomiasis, leptospirosis
Contact with soil (walking barefoot) Cutaneous larva migrans (hookworm, strongyloidiasis), tungiasis
Contact with animals Rabies, tularemia, Q fever, anthrax, viral hemorrhagic fevers, plaque, brucellosis
Dairy consumption Brucellosis, tuberculosis, shigellosis
Non-potable water consumption Hepatitis A and E, typhoid fever, amebiasis, giardiasis, cryptosporidiasis, shigellosis, 
cyclosporiasis 
Consumption of raw and undercooked food Hepatitis A, bacterial enteric infections, trichinosis, amebiasis, toxoplasmosis, cestodiasis
High-risk sexual contact AIDS, hepatitis B and C, herpes, gonorrhea, syphilis
Cave exploration Rabies, histoplasmosis
Contact with ill/infected patients Tuberculosis, invasive meningococcal disease, influenza, MERS-CoV, COVID-19, viral 
hemorrhagic fevers
Exposure to mosquitoes Malaria, dengue, chikungunya, zika, yellow fever, other arboviruses, filariasis
Exposure to tics Rickettsioses, borreliosis, Q fever, tularemia, Crimean-Congo hemorrhagic fever
Exposure to flies African trypanosomiasis, leshmaniasis, onchocerciasis, bartonellosis
Exposure to fleas Murine typhus, plague
Exposure to lice Exanthematic typhus, relapsing fever
Exposure to mites Scrub typhus
diarrhea, nausea, vomiting, respiratory symptoms, uri-
nary or genital disorders, dermatoses including jaundice, 
weight loss;
 — asymptomatic travelers who have a chronic illness, 
which may increase their risk of complications of trav-
el-related infection;
 — asymptomatic travelers who are immunocompromised 
(an immunological disorder, or medically induced im-
munosuppression);
 — asymptomatic travelers who have spent more than 
3 months in a country with harsh climate and poor 
standards of sanitation; 
 — asymptomatic travelers who might have been exposed 
to risk factors (non-compliance with disease prevention 
measures or antimalarial chemoprophylaxis, extreme 
sports, unsafe sex contacts, consumption of food or 
water from unsafe sources, etc.) [22, 23].
SYMPTOMATIC TRAVELERS
This group of travelers frequently consults a travel medi-
cine specialist to seek or to confirm a diagnosis established 
elsewhere or on their own. Another incentive to consult 
a physician is the fear of spreading the infection to oth-
er people (family, friends, co-workers). This is particularly 
important in case of airborne transmission (coronavirus 
infection, influenza), fecal-oral transmission (intestinal para-
sites, salmonellosis, shigellosis), direct contact transmission 
(scabies) and sexually transmitted diseases.
ASYMPTOMATIC SHORT-TERM TRAVELERS
Routine post-travel screening can be restricted to pa-
tients who report exposure to risk factors during their trav-
el, as well as patients who are immunocompromised or 
have chronic conditions. For those travelling on business, 
a post-travel screening procedure might be required by 
their employer (a compulsory periodic medical evaluation 
in occupational medicine).   
ASYMPTOMATIC LONG-TERM TRAVELERS
This group of patients will greatly benefit from a thorough 
medical interview to assess potential risk factors they might 
have been exposed to while staying in a developing country. 
The major risk factors will include: exposure to mosquitoes, 
sand flies, ticks (vector-borne diseases), exposure to contam-
inated freshwater (schistosomiasis, leptospirosis) or contam-
inated soil (tetanus, intestinal helminthiases), consumption 
of food or water from unsafe sources (water- and food-borne 
diseases), unprotected sexual contacts with casual partners 
(sexually transmitted diseases [STDs]), animal bites (rabies). 
If a specific exposure is identified, with a significant risk of 
infection, screening laboratory tests may be indicated.
ASYMPTOMATIC EXTREME/ADVENTUROUS 
TRAVELERS
When visiting countries with harsh environmental condi-
tions adventurous travelers frequently adopt lifestyles sim-
ilar to those of the local people, and therefore run a higher 
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risk of developing unusual infections. Infectious diseases 
which have a short incubation period are likely to become 
symptomatic during travel. When adventurous/extreme trav-
elers are asymptomatic, the following infections or illnesses 
may be suspected: schistosomiasis (bathing or swimming 
in contaminated freshwater lakes, ponds or rivers), histo-
plasmosis (exploring bat-infested caves), cutaneous larva 
migrans (walking barefoot in feces-contaminated soil), filari-
asis (mosquito bites), leishmaniasis (sand flies bites), AIDS 
(unprotected sex with new partners) [23].
POST-TRAVEL SCREENING
The risk of developing a travel-related health problem will 
depend on a variety of factors. The common risk factors usu-
ally include: the level of endemicity in the countries visited, 
the general health condition of a traveler (proper functioning 
of the immune and the thermoregulatory systems, chronic 
diseases), adoption of prophylactic measures, duration of 
travel, type of activities (a leisure holiday vs. extreme sports). 
In general, the risk of acquiring a travel-related disease is 
higher in tropical and subtropical destinations, which is 
associated with a higher risk of exposure to vector-borne, 
food and water-borne, airborne or sexually transmitted 
pathogens. The groups of travelers who run the highest 
risk of developing a travel-related illness include the elderly, 
young children, pregnant women, people with disabilities, 
patients with cancer, patients with circulatory system dis-
orders or renal disorders, diabetic patients, patients with 
thyroid disease, epilepsy or psychiatric disorders. Because 
of the rapidly increasing numbers of international tourist 
arrivals and the growing number of global health risk factors, 
post-travel screening has become a necessity. The introduc-
tion of screening test panels targeted at specific groups of 
travelers (depending on the type of clinical manifestations, 
risk exposure, countries visited) seem to be a good solution 
to the problem of travel-related health assessment. The 
pre-travel test panel is generally recommended for tourists 
with a history of chronic diseases (Table 5) [24].
A detailed medical interview is the basis of the post-trav-
el screening process. In order to establish an accurate 
diagnosis and implement effective treatment a health care 
provider will need the information on the patient’s past 
medical history, the symptoms which have occurred during 
or after travel, possible risk exposures and the list of coun-
tries the patient has visited. During a post-travel follow-up 
a doctor may inform the patient of the common routes 
of transmission (especially of the infectious and parasitic 
diseases) as it may help the patient identify potentially 
risky exposures (Table 4). It is important to remember that 
a considerable proportion of travel-related infections might 
be asymptomatic (numerous parasitic diseases) and that it 
would be impossible to detect certain infections during the 
window period, i.e. the period from infection to when the body 
products enough antibodies to be detected by laboratory tests 
(the window period for human immunodeficiency virus (HIV) 
may be up to 12 weeks). A popular method used for screening 
returned travelers is to perform qualitative rapid diagnostic 
tests, however, when it is important to assess the intensity of 
the invasion (as in schistosomiasis, some filarial infections) 
quantitative and semi-quantitative tests will be more useful. 
If an asymptomatic patient seeks medical help shortly after 
returning from a country where infectious diseases are endemic 
or where there has been an outbreak of an infectious disease, or 
if a patient had significant risk exposure during travel, a health 
care provider should inform him of the necessity to report for 
a follow-up screening 3 months after the initial tests (to confirm 
or rule out infections which have longer incubation and latent 
periods (tuberculosis, benign tertian malaria, amebic liver ab-
scess, acute schistosomiasis, acute HIV seroconversion) [23].
The diagnostic procedures for common tropical and 
cosmopolitan infections in asymptomatic travelers who 
have returned from tropical or subtropical destinations are 
presented in Table 6.
BASIC LABORATORY TESTS
A basic set of laboratory tests includes a total blood 
count with differential, liver enzymes levels (ALT, AST, ALP, 
BR, GTP), creatinine, and CRP. These tests provide general 
information on potential infections and systemic inflamma-
tion and are useful in detecting any changes in the blood 
count (leukocytosis, leukopenia, anemia, thrombocytopenia, 
eosinophilia) as well as any dysfunction of liver or kidney. 
Urinalysis, including urine microscopy and testing for pro-
teinuria, is essential when urinary tract infection is suspect-
ed, but generally fails to provide useful information on other 
diseases in asymptomatic patients [12, 23].
BLOOD EOSINOPHIL COUNT
Absolute eosinophil count (i.e. calculating the number 
of eosinophils in peripheral blood sample) may be used to 
detect parasitic infections, but also some allergic or respi-
ratory infections. Eosinophilia is defined as an increased 
blood eosinophil count > 4% and is usually associated with 
parasitic diseases, such as schistosomiasis, strongyloido-
sis, ascariasis, hookworm infection, trichinosis, lymphatic 
filarioses (wuchereriosis), cutaneous and subcutaneous 
filarioses (loiasis, onchocerciasis), fasciolosis. Eosinophilia 
is usually more pronounced when parasites migrate through 
the blood or tissues, as in infections caused by the migra-
tory intestinal helminths. However, in most patients with 
an asymptomatic parasitic infection, the eosinophil count 
is normal. Eosinophilia may also be associated with some 
infectious diseases, e.g. HIV infections, coccidioidomycosis, 
aspergillosis, tuberculosis and syphilis [11, 12, 25, 26]. 
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Table 5. Screening test panels recommended for travelers [24]
No. Screening test panel Laboratory tests included
1 Pre-travel assessment panel ESR, blood count with differential; urinalysis; urea, creatinine; liver enzymes  
(ALT, AST, ALP, BR, GGTP); routine tests for chronic diseases a traveler may have
2 Post-travel assessment panel 
(asymptomatic patients)
ESR, blood count with differential; urinalysis, creatinine; liver enzymes (ALT, AST, ALP, BR, 
GGTP); CRP, quantitative; multiple stool microscopy, three samples (intestinal parasites) 
3 Post-travel assessment panel 
(gastrointestinal symptoms)
ESR, blood count with differential; liver enzymes (ALT, AST, ALP, BR, GGTP); CRP, 
quantitative; HAV, HEV IgM/IgG; gastrointestinal panel including 25 pathogens (Norovirus, 
Adenovirus, Sapovirus, Rotavirus, Astrovirus, STEC, EPEC, ETEC, EAEC, E. coli O157, 
Shigella spp., Salmonella spp., Aeromonas spp., Campylobacter spp., Clostridium difficile 
toxin A, Yersinia enterocolitica, Vibrio spp., Dientamoeba fragilis, Blastocystis spp., 
Cryptosporidium spp., Cyclospora cayetanensis, Giardia lamblia, Entamoeba histolytica), 
real-time PCR; multiple stool microscopy, three samples (intestinal parasites)
4 Post-travel assessment panel 
(respiratory symptoms)
ESR, blood count with differential; CRP, quantitative; respiratory panel including  
26 pathogens (Flu A, Flu B, RSV A, RSV B, Flu A-H1, Flu A-H1pdm09, Flu A-H3, Adenovirus, 
Enterovirus, Parainfluenza virus 1,2,3,4, Metapneumovirus, Bocavirus, Rhinovirus, 
Coronavirus NL63, 229E, OC43, Mycoplasma pneumoniae, Chlamydophila pneumoniae, 
Legionella pneumophila, Haemophilus influenzae, Streptococcus pneumoniae, Bordetella 
pertussis, Bordetella parapertussis), real-time PCR
5 Post-travel assessment panel  
(fever of unknown origin)
ESR, blood count with differential; urinalysis, urine culture (bacteriological test); CRP, 
quantitative; malaria (Plasmodium spp.), parasitemia, blood microscopy; HAV, HEV  
IgM/IgG; dengue IgM/IgG; chikungunya IgM/IgG; zika IgM/IgG; gastrointestinal pathogen 
panel including 25 pathogens (see section 3), real-time PCR
6 Post-travel assessment panel 
(exposure to risk factors: unsafe 
sex with casual partners, injections, 
tattooing, piercing)
HBs Ag; HCV; HIV; syphilis (Treponema pallidum) IgM/IgG; urogenital panel (Chlamydia 
trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Mycoplasma hominis, 
Ureaplasma urealyticum, Trichomonas vaginalis), real-time PCR
7 Post-travel assessment panel  
for travelers returning from 
Mediterranean countries  
(Europe, North Africa)
HAV, HEV IgM/IgG; gastrointestinal pathogen panel including 25 pathogens (see section 3), 
real-time PCR; dengue IgM/IgG; chikungunya IgM/IgG; zika IgM/IgG; urine culture 
(bacteriological test); multiple stool microscopy, three samples (intestinal parasites)
8 Post-travel assessment panel for 
travelers returning from Sub-Saharan 
Africa, South and South-East Asia
Malaria (Plasmodium spp.) parasitemia, blood microscopy; HAV, HEV IgM/IgG; 
gastrointestinal pathogens panel including 25 pathogens (see section 3), real-time PCR; 
dengue IgM/IgG; chikungunya IgM/IgG; zika IgM/IgG; urine culture (bacteriological test); 
multiple stool microscopy, three samples (intestinal parasites)
9 Post-travel assessment panel for 
travelers returning from Central 
America/the Caribbean or South 
America
Malaria (Plasmodium spp.) parasitemia, blood microscopy; HAV, HEV IgM/IgG; 
gastrointestinal pathogens panel including 25 pathogens (see section 3), real-time PCR; 
dengue IgM/IgG; chikungunya IgM/IgG; zika IgM/IgG; urine culture (bacteriological test); 
multiple stool microscopy, three samples (intestinal parasites)
ALP — alkaline phosphatase; ALT — alanine aminotransferase; AST — aspartate aminotransferase; BR — bilirubin; CRP — C-reactive protein; ESR — erythrocyte sedimenta-
tion rate; GGTP — gamma glutamyl transpeptidase; HAV — hepatitis A virus; HEV — hepatitis E virus; HCV — hepatitis C virus; HIV — human immunodeficiency virus;  
PCR — polymerase chain reaction  
ABDOMINAL ULTRASOUND
The test may be considered as a secondary diagnostic 
procedure in asymptomatic travelers presenting with ab-
normal liver and/or renal function tests and/or abnormal 
urinalysis [23].
RESTING ELECTROCARDIOGRAM
The test may be useful in identifying patients with the 
‘long QT’ syndrome, who are at a higher risk of malignant 
ventricular tachycardia when treated with antimalarial med-
ications (quinine, quinidine). Electrocardiogram can also 
help detect atrioventricular conduction problems, which are 
a contraindication to the use of mefloquine [23].
INTESTINAL PARASITIC DISEASES
Travelers returning from developing countries where 
intestinal parasitoses are endemic should be screened for 
parasitic infections (travelers may transmit the infection 
to others, even if they are asymptomatic). To establish an 
accurate diagnosis, it is essential to select the most reliable 
diagnostic method; the ‘gold standard’ for the diagnosis 
of intestinal parasitic infections is multiple stool micros-
copy using different techniques (direct smear, flotation, 
sedimentation). To differentiate between similar parasitic 
species (e.g. the pathogenic Entamoeba histolytica from 
non-pathogenic Entamoeba dispar) molecular techniques 
are recommended (PCR) [11, 27, 28]. 
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Table 6. Diagnostics of common travel-related infections in asymptomatic travelers [23]    
Disease Incubation period Diagnostic procedure Time lapse after which 
asymptomatic infection 
becomes very unlikely 
(given negative screen)
Amebiasis Days – > 6 months Stool microscopy (infection with E. histolytica/E. dispar)
Stool PCR for Entamoeba histolytica, serum antibody test 
(infection E. histolytica, tissue invasion E. histolytica)
6 months (may be longer, 
even years)
Malaria  
(P. falciparum)
9–30 days Thick film, malaria antigen test (parasitemia in semi-immune)
HRP-2 antigen test (confirmation of recent infection/diseases)
Serum antibody test (post-infection confirmation and chronic 
suppressed infection)
Non-immunes: 3 months
Semi-immunes: 4 years
Malaria  
(P. vivax, P. ovale, 
P. malariae)
8 days – > 12 months Thick film, malaria antigen test (active infection/disease)
Serum antibody test P. vivax, P. ovale (post-infection 
confirmation; interspecies cross reactions can occur)
Benign P. vivax, P. ovale: 
2–4 years
P. malariae: > 10 years
Typhoid fever 7–18 days  
(range 3–60 days)
Stool culture (convalescent carrier state)
Serum antibody test Widal (negative test excludes recent 
infection, poor specificity) 
2 months
Tuberculosis > 30 days Tuberculin test (asymptomatic infection)
IGRA (asymptomatic infection in BCG vaccinees)
2–4 months (asymptomatic 
infection — risk lifelong)
Schistosomiasis 14 – > 60 days Serum antibody test (asymptomatic infection) 3–6 months  
(exceptionally longer)
Intestinal 
helminths
3 – > 60 days Stool microscopy (active infection) 2 months
Filariasis 
(Wuchereria 
bancrofti)
? – > 12 months Serum antibody test (exposure or active infection)
Serum antigen test (active infection)
Nocturnal microfilaremia (active infection)
Up to 2 years
Filariasis 
(Onchocerca 
volvulus)
3 – > 15 months Serum antibody test (exposure; low sensitivity)
Ocular microfilaria (active infection; requires  
ophthalmologic examination)
Up to 2 years
Filariasis (Loa loa) ? – > 12 months Serum antibody test (exposure or active infection)
Daytime microfilaremia (active infection)
Up to 2 years
Strongyloidiasis 7 – > 21 days Serum antibody test (exposure, active infection;  
sensitive, non-specific)
Stool microscopy (concentration technique)  
or stool PCR or antigen test (active infection)
1 month
HIV 14 – > 90 days Serum antigen/antibody test HIV-ELISA/p-24  
(active infection: screening)
6 weeks – 6 months
Syphilis 9 – > 90 days VDRL (active infection)
TPHA, FTA (confirmation, post-exposure, post-treatment)
3 months
Hepatitis B 90 days  
(range 2–6 months)
Serum antigen test HBsAg (active or latent infection/disease)
Serum antibody test HBsAb, HBV DNA (immunity,  
classification of infection activity)
6 months
Hepatitis C 2 weeks – 6 months Serum antibody test (active or latent infection/disease)
HCV RNA (confirmation of active infection)
6 months
Chagas disease 
(Trypanosoma 
cruzi)
5–14 days Serum antibody test (latent or active infection)
PCR (active infection)
To be followed up 
serologically until 6 months 
after possible exposure
BCG — Bacillus Calmette-Guerin; CRP — C-reactive protein; FTA — fluorescent treponemal antibody absorption; HBV DNA — hepatitis B virus DNA; HCV RNA — hepatitis B 
virus RNA; HRP-2 — histidine-rich protein 2; GGTP — gamma glutamyl transpeptidase; HIV — human immunodeficiency virus; IGRA — interferon-gamma release assay;  
PCR — polymerase chain reaction; TPHA— treponema pallidum hemagglutination assay; VDRL — venereal disease research laboratory test
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SEXUALLY TRANSMITTED DISEASES
Post-travel screening is recommended in travelers 
with a history of unprotected sexual contacts with casual 
partners (including commercial sex workers). It should 
involve detection of HIV, syphilis, gonorrhea, chlamydia-
sis, hepatitis B and C, genital herpes (HSV), condylomata 
acuminata (HPV), and tropical STDs (e.g. chancroid). In 
patients returning from endemic regions the medical in-
terview will be the foundation of the post-travel screening 
process (a physician should consider the time of exposure, 
the incubation period and the window period, as in HIV 
infection) [29]. The PCR tests for gonorrhea or chlamydi-
asis may be performed on urine samples [30]. Travelers 
who received blood transfusions during their stay in de-
veloping countries, where blood screening procedures are 
often less complete, should be tested for AIDS, syphilis, 
hepatitis B and C [23].
CONCLUSIONS
A medical interview by an experienced physician forms 
the basis of the post-travel screening process both in symp-
tomatic as well as asymptomatic travelers. The interview 
should primarily focus on identifying exposure to risk fac-
tors (endemic infectious diseases, failure to adopt disease 
prevention measures, consumption of food or water from 
unsafe sources, insect bites, animal bites, travelling in large 
groups, unsafe sex with casual partners). While physical ex-
amination (identification of abnormalities) and a well-chosen 
set of diagnostic tests (identification of pathogens) can be 
useful to detect illnesses and asymptomatic infections as 
well as assess the general health condition of a patient and 
his immune status.
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